Apogee Therapeutics Inc 's (APGE) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Apogee Therapeutics Inc   (NASDAQ: APGE)
 



  Apogee Therapeutics Inc Outlook

On May 13 2024 the Apogee Therapeutics Inc provided following guidance

Apogee Therapeutics Inc. has made significant progress in its pipeline, including the initiation of a Phase 2 clinical trial for APG777. This drug is a subcutaneous half-life extended monoclonal antibody that targets IL-13 and is being tested in patients with moderate-to-severe atopic dermatitis. The company expects to receive 16-week proof-of-concept data from Part A of the trial in the second half of 2025. This trial marks a significant milestone for Apogee Therapeutics as it continues to advance its pipeline of innovative therapies.

Additionally, Apogee Therapeutics reported its first quarter financial results for 2024. The company remains optimistic about its financial outlook and is committed to delivering value to its shareholders. These developments demonstrate Apogee Therapeutics' commitment to advancing novel treatments for patients in need.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.